PT-141

PT-141 (Bremelanotide): Comprehensive Research Guide

PT-141, also known as Bremelanotide, is a synthetic peptide that has gained significant attention in the research community for its remarkable effects on sexual function, libido, and sexual arousal. This 7-amino-acid peptide, with a cyclic structure and a modified amino acid sequence, was developed as a more stable and potent analog of alpha-melanocyte-stimulating hormone (α-MSH). PT-141 has been extensively studied for its effects on sexual desire, erectile function, sexual arousal, and overall sexual performance in both men and women. It is the first medication approved by the FDA for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, under the brand name Vyleesi®.

At Hanpro Peptides, we provide the highest purity PT-141 for research purposes only. Our products are manufactured in state-of-the-art facilities and undergo rigorous quality testing to ensure 99%+ purity. This comprehensive guide covers everything researchers need to know about PT-141, including its molecular structure, mechanisms of action, research applications, proper handling, and frequently asked questions.

Molecular Structure and Properties

PT-141 (Bremelanotide) is a cyclic heptapeptide (7 amino acids) with the molecular formula C₅₀H₆₈N₁₄O₁₀ and a molecular weight of approximately 1025.2 g/mol. Its amino acid sequence is: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. The peptide is a modified analog of alpha-melanocyte-stimulating hormone (α-MSH), with several key modifications that enhance its stability, potency, and bioavailability.

The key structural features of PT-141 include: (1) A cyclic structure, formed by a lactam bond between the side chain of the aspartic acid (Asp) residue and the side chain of the lysine (Lys) residue. This cyclic structure enhances the stability of the peptide by protecting it from enzymatic degradation, and it also constrains the peptide into a specific conformation that is optimal for receptor binding. (2) Substitution of the methionine (Met) residue at position 4 with norleucine (Nle), which enhances the stability of the peptide by preventing oxidation of the methionine sulfur atom, and also enhances the potency and receptor binding affinity of the peptide. (3) Substitution of the L-phenylalanine (L-Phe) residue at position 7 with D-phenylalanine (D-Phe), which enhances the stability of the peptide by protecting it from enzymatic degradation by proteases that specifically recognize L-amino acids, and also enhances the potency and receptor selectivity of the peptide. (4) Acetylation of the N-terminus (Ac-) and amidation of the C-terminus (-NH2), which further enhances the stability of the peptide by protecting it from exopeptidases (enzymes that degrade peptides from the ends), and also enhances the receptor binding affinity and bioavailability of the peptide.

PT-141 is highly soluble in water and physiological buffers, and it is stable under a wide range of pH and temperature conditions. The peptide’s cyclic structure and modified amino acid sequence make it highly resistant to enzymatic degradation, resulting in a prolonged half-life of approximately 2-3 hours in humans, which is significantly longer than the half-life of native α-MSH (approximately 1-2 minutes). PT-141 is available in both injectable (subcutaneous) and intranasal formulations, with the injectable formulation being the most widely used in research and clinical settings.

Mechanisms of Action

PT-141 exerts its effects through multiple interconnected mechanisms, primarily by acting as a potent agonist of the melanocortin receptors, particularly the MC4 receptor. Understanding these mechanisms is crucial for designing effective research studies and interpreting results.

1. Melanocortin Receptor Agonism: The primary mechanism of PT-141 is its ability to bind to and activate the melanocortin receptors, a family of G-protein-coupled receptors that includes five subtypes (MC1-MC5). PT-141 is a non-selective agonist of the melanocortin receptors, with the highest affinity and potency for the MC4 receptor, followed by the MC3 receptor, and lower affinity for the MC1, MC2, and MC5 receptors. Activation of the melanocortin receptors stimulates adenylate cyclase, increasing intracellular cyclic AMP (cAMP) levels and activating downstream signaling pathways, including protein kinase A (PKA) and cAMP response element-binding protein (CREB). These signaling pathways mediate the various physiological effects of PT-141, including sexual arousal, appetite regulation, energy metabolism, inflammation, and pigmentation. The MC4 receptor, in particular, is highly expressed in the hypothalamus and other brain regions involved in sexual function, appetite regulation, and energy homeostasis, and it is the primary receptor responsible for the pro-sexual and appetite-suppressing effects of PT-141.

2. Sexual Arousal and Libido Enhancement: One of the most well-established and clinically significant effects of PT-141 is its ability to enhance sexual arousal and libido in both men and women. This effect is mediated primarily through activation of the MC4 receptor in the hypothalamus and other brain regions involved in sexual function, including the paraventricular nucleus (PVN) of the hypothalamus, the medial preoptic area (MPOA), and the amygdala. Activation of MC4 receptors in these brain regions increases the release of various neurotransmitters involved in sexual arousal, including dopamine, norepinephrine, oxytocin, and nitric oxide (NO). Dopamine, in particular, plays a key role in sexual desire and arousal, and PT-141 has been shown to increase dopamine release in the hypothalamus and other brain regions involved in sexual function. PT-141 also increases the release of oxytocin, a hormone involved in sexual arousal, bonding, and orgasm, and it increases the production of nitric oxide (NO), a key mediator of penile erection and vaginal engorgement. Unlike medications such as sildenafil (Viagra) and tadalafil (Cialis), which work by increasing blood flow to the genitals but do not directly affect sexual desire or libido, PT-141 works centrally in the brain to increase sexual desire and arousal, making it effective for both physical and psychological causes of sexual dysfunction.

3. Erectile Function Improvement: In addition to enhancing sexual desire and libido, PT-141 also improves erectile function in men with erectile dysfunction (ED). This effect is mediated through both central and peripheral mechanisms. Centrally, activation of MC4 receptors in the hypothalamus increases the release of dopamine and oxytocin, which stimulate the parasympathetic nervous system and increase the production of nitric oxide (NO) in the penile corpus cavernosum. Peripherally, PT-141 may also directly activate MC4 receptors expressed in the penile corpus cavernosum, increasing the production of NO and promoting smooth muscle relaxation, vasodilation, and increased blood flow to the penis, resulting in penile erection. In clinical trials, PT-141 has been shown to improve erectile function in men with ED, including men who do not respond to phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil and tadalafil. This is particularly important, as approximately 30-50% of men with ED do not respond adequately to PDE5 inhibitors, and PT-141 may provide an effective alternative treatment option for these men.

4. Female Sexual Function Improvement: PT-141 has also been shown to improve sexual function in women with sexual dysfunction, particularly hypoactive sexual desire disorder (HSDD), a condition characterized by persistently low sexual desire that causes personal distress. In clinical trials, PT-141 (administered as an intranasal spray) has been shown to significantly increase sexual desire, reduce sexual distress, and increase the number of satisfying sexual events in premenopausal women with HSDD. This effect is mediated through activation of MC4 receptors in the hypothalamus and other brain regions involved in sexual function, increasing the release of dopamine, oxytocin, and other neurotransmitters involved in sexual arousal and desire. PT-141 also increases vaginal engorgement and lubrication through increased NO production and vasodilation in the genital tissues, similar to its effects on penile erection in men. In 2019, the FDA approved PT-141 (bremelanotide) under the brand name Vyleesi® for the treatment of HSDD in premenopausal women, making it the first medication approved for this indication. PT-141 is also being investigated for the treatment of sexual dysfunction in postmenopausal women and in women with other types of sexual dysfunction, including female sexual arousal disorder (FSAD) and sexual pain disorders.

5. Appetite Suppression and Weight Loss: In addition to its effects on sexual function, PT-141 also has significant effects on appetite regulation and body weight, mediated primarily through activation of MC4 receptors in the hypothalamus. The MC4 receptor is a key regulator of appetite and energy homeostasis, and activation of MC4 receptors in the hypothalamus (particularly in the paraventricular nucleus and the arcuate nucleus) suppresses appetite, increases energy expenditure, and promotes weight loss. In preclinical studies, PT-141 has been shown to reduce food intake and body weight in various animal models of obesity, including diet-induced obesity and genetic obesity. In clinical trials, PT-141 has also been shown to reduce appetite and food intake in humans, although the weight loss effects are generally less pronounced than the sexual effects, and weight loss is often considered a side effect rather than a primary therapeutic effect. The appetite-suppressing effects of PT-141 may be particularly useful for patients with sexual dysfunction who are also overweight or obese, as it may provide additional metabolic benefits in addition to improving sexual function.

6. Anti-Inflammatory and Immunomodulatory Effects: PT-141 also has anti-inflammatory and immunomodulatory effects, mediated through activation of melanocortin receptors (particularly MC1 and MC3 receptors) on immune cells and endothelial cells. Activation of melanocortin receptors on immune cells inhibits the production of pro-inflammatory cytokines (such as TNF-α, IL-1β, and IL-6), reduces the activation and proliferation of immune cells, and promotes the resolution of inflammation. Activation of melanocortin receptors on endothelial cells reduces endothelial activation, reduces the expression of adhesion molecules, and inhibits the recruitment of immune cells to sites of inflammation. In preclinical studies, PT-141 has been shown to reduce inflammation and tissue damage in various animal models of inflammatory disease, including rheumatoid arthritis, inflammatory bowel disease, sepsis, and acute lung injury. The anti-inflammatory effects of PT-141 may also contribute to its beneficial effects on sexual function, as chronic inflammation and endothelial dysfunction are known to contribute to sexual dysfunction in both men and women.

7. Cardiovascular and Metabolic Effects: PT-141 also has significant effects on cardiovascular function and metabolic health, mediated through activation of melanocortin receptors in the cardiovascular system, adipose tissue, liver, and skeletal muscle. Activation of melanocortin receptors in the cardiovascular system can cause transient increases in blood pressure and heart rate, particularly at higher doses, which is one of the main side effects of PT-141. However, at therapeutic doses, the cardiovascular effects are generally mild and transient, and they do not appear to be associated with significant long-term cardiovascular risk. Activation of melanocortin receptors in adipose tissue, liver, and skeletal muscle improves insulin sensitivity, reduces hepatic glucose production, increases fatty acid oxidation, and improves overall metabolic health. In preclinical studies, PT-141 has been shown to improve glucose tolerance and insulin sensitivity in animal models of obesity and type 2 diabetes, and to reduce liver fat accumulation and hepatic steatosis. The metabolic effects of PT-141 may be particularly beneficial for patients with sexual dysfunction who also have metabolic syndrome or type 2 diabetes, as these conditions are closely associated with sexual dysfunction.

Research Applications

PT-141 has been investigated in numerous preclinical and clinical studies for its potential therapeutic applications across various medical fields. The following sections highlight the most important areas of research.

1. Male Sexual Dysfunction

One of the primary and most well-studied applications of PT-141 is in the treatment of male sexual dysfunction, including erectile dysfunction (ED), low libido (hypoactive sexual desire disorder), and sexual arousal disorder. PT-141 works centrally in the brain to increase sexual desire and arousal, and it also improves erectile function through increased nitric oxide production and blood flow to the penis. Unlike PDE5 inhibitors (such as sildenafil and tadalafil), which work by increasing blood flow to the penis but do not directly affect sexual desire, PT-141 works by increasing sexual desire and arousal in the brain, making it effective for both physical and psychological causes of sexual dysfunction.

Numerous preclinical studies in animal models have shown that PT-141 increases sexual behavior, including mounting, intromission, and ejaculation, in male rats and other animal models, even in castrated males and in males with experimentally induced erectile dysfunction. PT-141 has also been shown to increase sexual motivation and arousal in animal models, as measured by increased time spent near sexually receptive females and increased anticipatory behavior before mating.

In clinical trials, PT-141 (administered as a subcutaneous injection or intranasal spray) has been shown to improve erectile function, increase sexual desire, and increase the number of successful sexual encounters in men with ED, including men who do not respond to PDE5 inhibitors. In a phase 2 clinical trial, men with ED who received PT-141 (subcutaneous injection) reported significant improvements in erectile function, sexual desire, and overall sexual satisfaction compared to men who received placebo, with the greatest improvements observed in men with both ED and low libido. In another phase 2 clinical trial, men with ED who did not respond to sildenafil (Viagra) reported significant improvements in erectile function and sexual satisfaction when treated with PT-141, suggesting that PT-141 may be an effective alternative for men who do not respond to PDE5 inhibitors.

PT-141 has also been investigated for the treatment of low libido (hypoactive sexual desire disorder) in men, a condition that is often overlooked and for which there are currently no FDA-approved treatments. In clinical trials, men with low libido who received PT-141 reported significant increases in sexual desire, sexual motivation, and the number of satisfying sexual events compared to men who received placebo. The effects of PT-141 on sexual desire in men appear to be dose-dependent, with higher doses producing greater increases in sexual desire, although higher doses are also associated with a higher incidence of side effects, particularly nausea and flushing.

The safety and tolerability of PT-141 in men have been generally good in clinical trials, with the most common side effects being nausea, flushing, headache, and transient increases in blood pressure. These side effects are generally mild to moderate in severity, occur primarily within the first 1-2 hours after administration, and tend to diminish over time with repeated use. The incidence of side effects is dose-dependent, with higher doses associated with a higher incidence of side effects. To minimize side effects, PT-141 is typically initiated at a low dose and gradually titrated up to the effective dose based on individual response and tolerability. It is important to note that PT-141 can cause transient increases in blood pressure and heart rate, particularly at higher doses, and it should be used with caution in men with uncontrolled hypertension or cardiovascular disease. However, at therapeutic doses, the cardiovascular effects are generally mild and transient, and they do not appear to be associated with significant long-term cardiovascular risk.

2. Female Sexual Dysfunction

One of the most significant and clinically important applications of PT-141 is in the treatment of female sexual dysfunction, particularly hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is a common condition characterized by persistently low sexual desire that causes personal distress, affecting approximately 10-15% of premenopausal women and up to 30-40% of postmenopausal women. Despite its prevalence, there are few effective treatments for HSDD, and until the approval of PT-141 (bremelanotide) in 2019, there were no FDA-approved treatments for HSDD in premenopausal women.

Numerous preclinical studies in animal models have shown that PT-141 increases sexual behavior and sexual motivation in female rats and other animal models, including increased receptivity to males, increased proceptive behavior (solicitation of males), and increased sexual motivation as measured by increased time spent near sexually active males. PT-141 has also been shown to increase genital arousal and vaginal engorgement in animal models, through increased nitric oxide production and vasodilation in the genital tissues.

In clinical trials, PT-141 (administered as an intranasal spray under the brand name Vyleesi®) has been shown to significantly increase sexual desire, reduce sexual distress, and increase the number of satisfying sexual events in premenopausal women with HSDD. In two phase 3 clinical trials (RECONNECT trials), premenopausal women with HSDD who received PT-141 (1.75 mg intranasal spray, as needed, approximately 45 minutes before sexual activity) reported significant improvements in sexual desire, reductions in sexual distress, and increases in the number of satisfying sexual events compared to women who received placebo. The improvements in sexual desire were observed as early as the first month of treatment, and they were maintained throughout the 24-week treatment period. The most common side effects were nausea, flushing, headache, and vomiting, which were generally mild to moderate in severity and occurred primarily within the first 1-2 hours after administration.

Based on the positive results of the RECONNECT phase 3 trials, the FDA approved PT-141 (bremelanotide) under the brand name Vyleesi® in June 2019 for the treatment of HSDD in premenopausal women, making it the first medication approved for this indication. Vyleesi® is administered as an intranasal spray, as needed, approximately 45 minutes before anticipated sexual activity, and it is not intended for daily use. The recommended dose is 1.75 mg per administration, with no more than one dose per 24-hour period and no more than 8 doses per month.

PT-141 is also being investigated for the treatment of sexual dysfunction in postmenopausal women, including HSDD, female sexual arousal disorder (FSAD), and sexual pain disorders. In preliminary clinical trials, PT-141 has been shown to improve sexual desire, sexual arousal, and sexual satisfaction in postmenopausal women with sexual dysfunction, although the results have been somewhat less consistent than in premenopausal women. Larger clinical trials are needed to confirm the efficacy and safety of PT-141 in postmenopausal women and to determine the optimal dose and treatment regimen for this population.

PT-141 has also been investigated for the treatment of sexual dysfunction in women with other medical conditions, including breast cancer survivors (who often experience sexual dysfunction as a result of chemotherapy, hormonal therapy, and surgical menopause), women with multiple sclerosis (who often experience sexual dysfunction as a result of neurological damage), and women with spinal cord injuries (who often experience sexual dysfunction as a result of neurological damage). In preliminary studies, PT-141 has shown promise in improving sexual function in these populations, although larger clinical trials are needed to confirm these results.

3. Obesity and Metabolic Syndrome

In addition to its effects on sexual function, PT-141 also has significant effects on appetite regulation, energy metabolism, and body weight, mediated primarily through activation of MC4 receptors in the hypothalamus. The MC4 receptor is a key regulator of appetite and energy homeostasis, and genetic mutations that cause MC4 receptor deficiency are the most common known genetic cause of severe obesity in humans, accounting for approximately 5-6% of cases of severe early-onset obesity. This suggests that activation of MC4 receptors may be an effective strategy for the treatment of obesity and metabolic syndrome.

Numerous preclinical studies in animal models have shown that PT-141 and other melanocortin receptor agonists reduce food intake, increase energy expenditure, and promote weight loss in various animal models of obesity, including diet-induced obesity, genetic obesity (such as ob/ob mice and db/db mice), and MC4 receptor deficiency. In mice with diet-induced obesity, chronic administration of PT-141 has been shown to reduce food intake by 20-40%, increase energy expenditure by 10-20%, and reduce body weight by 15-30% over several weeks of treatment. PT-141 has also been shown to reduce body fat mass, particularly visceral fat, and to preserve lean body mass during weight loss, which is important for maintaining metabolic health and physical function. In addition to weight loss, PT-141 has also been shown to improve glucose tolerance, insulin sensitivity, and lipid profiles in animal models of obesity and type 2 diabetes, and to reduce liver fat accumulation and hepatic steatosis.

The mechanisms by which PT-141 exerts its anti-obesity and metabolic effects include: (1) Suppression of appetite and food intake, through activation of MC4 receptors in the paraventricular nucleus (PVN) and other hypothalamic regions involved in appetite regulation; (2) Increase in energy expenditure and thermogenesis, through activation of MC4 receptors in the hypothalamus and sympathetic nervous system, which increases the activity of brown adipose tissue (BAT) and promotes the browning of white adipose tissue (WAT); (3) Improvement of insulin sensitivity and glucose homeostasis, through both direct effects on insulin signaling pathways and indirect effects through weight loss and reduced inflammation; (4) Reduction of hepatic glucose production and hepatic steatosis, through activation of MC4 receptors in the liver and through improved insulin sensitivity; (5) Improvement of lipid profiles, including reduction of triglycerides and LDL cholesterol, and increase of HDL cholesterol, through both direct effects on lipid metabolism and indirect effects through weight loss.

While the preclinical evidence for the anti-obesity and metabolic effects of PT-141 is strong, the clinical evidence in humans is more limited, primarily because the clinical development of PT-141 has focused on its sexual function effects rather than its weight loss effects. In clinical trials for sexual dysfunction, PT-141 has been shown to reduce appetite and food intake in some patients, and to cause modest weight loss (1-3 kg) over several months of treatment, although the weight loss effects are generally less pronounced than the sexual effects. It is possible that higher doses or more frequent administration of PT-141 may produce more significant weight loss in humans, but this has not been extensively studied due to concerns about side effects, particularly nausea and transient increases in blood pressure, at higher doses.

More recently, newer and more selective MC4 receptor agonists (such as setmelanotide, which is approved for the treatment of genetic obesity caused by MC4 receptor pathway deficiencies) have been developed that have more potent weight loss effects and fewer side effects than PT-141, and these newer agents are being investigated for the treatment of common obesity and metabolic syndrome. However, PT-141 may still be useful for the treatment of sexual dysfunction in patients who are also overweight or obese, as it may provide additional metabolic benefits in addition to improving sexual function. Additionally, the combination of PT-141 with other weight loss medications (such as GLP-1 receptor agonists) may produce synergistic weight loss effects while also improving sexual function, and this is an active area of research.

4. Other Research Applications

In addition to the well-established applications in sexual dysfunction and obesity, PT-141 has been investigated in several other research areas, with promising preliminary results.

Inflammatory and Autoimmune Diseases: PT-141 has potent anti-inflammatory and immunomodulatory effects, mediated through activation of melanocortin receptors on immune cells and endothelial cells. In preclinical studies, PT-141 has been shown to reduce inflammation and tissue damage in various animal models of inflammatory and autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), sepsis, acute lung injury/ARDS, psoriasis, and multiple sclerosis. The anti-inflammatory effects of PT-141 are mediated through inhibition of pro-inflammatory cytokine production, reduction of immune cell activation and proliferation, inhibition of endothelial activation and adhesion molecule expression, and promotion of the resolution of inflammation. While the preclinical evidence is strong, clinical trials of PT-141 for inflammatory diseases are limited, and more research is needed to determine the safety and efficacy of PT-141 for these indications in humans.

Cardiovascular Disease: PT-141 has complex effects on the cardiovascular system, with both potentially beneficial and potentially harmful effects. On one hand, PT-141 can cause transient increases in blood pressure and heart rate, particularly at higher doses, which may be harmful in patients with uncontrolled hypertension or cardiovascular disease. On the other hand, PT-141 has anti-inflammatory, anti-atherosclerotic, and endothelial-protective effects that may be beneficial for cardiovascular health, and its weight loss and metabolic effects may also reduce cardiovascular risk. In preclinical studies, PT-141 has been shown to reduce atherosclerotic plaque formation, reduce vascular inflammation, improve endothelial function, and reduce myocardial ischemia-reperfusion injury in animal models. However, the cardiovascular effects of PT-141 in humans are not fully understood, and more research is needed to determine the long-term cardiovascular safety and potential benefits of PT-141, particularly in patients with cardiovascular disease.

Neurological and Psychiatric Disorders: PT-141 has effects on various neurotransmitter systems in the brain, including dopamine, serotonin, norepinephrine, and oxytocin, and it has been investigated for the treatment of various neurological and psychiatric disorders, including depression, anxiety, schizophrenia, and substance use disorders. In preclinical studies, PT-141 has been shown to have antidepressant and anxiolytic effects in animal models of depression and anxiety, and to reduce drug-seeking behavior in animal models of substance use disorders (including alcohol, cocaine, and opioid addiction). The mechanisms of these effects are not fully understood, but they may involve modulation of dopamine and other neurotransmitter systems in the brain’s reward and motivation pathways. Clinical trials of PT-141 for neurological and psychiatric disorders are limited, and more research is needed to determine the safety and efficacy of PT-141 for these indications in humans.

Skin Disorders and Pigmentation: PT-141 is an agonist of the MC1 receptor, which is expressed in melanocytes (pigment-producing cells in the skin) and plays a key role in regulating skin pigmentation. Activation of MC1 receptors stimulates melanin production and skin tanning, and PT-141 has been investigated as a potential “tanning agent” or “sunless tanning” product. In clinical trials, PT-141 (administered as a subcutaneous injection or intranasal spray) has been shown to increase skin pigmentation and tanning in fair-skinned individuals, even without sun exposure, and to reduce the risk of sunburn and UV-induced skin damage. However, the use of PT-141 as a tanning agent is controversial, as it may encourage excessive sun exposure and increase the risk of skin cancer, and it is not approved for this indication. PT-141 has also been investigated for the treatment of skin disorders characterized by hypopigmentation (loss of skin pigment), such as vitiligo, although the results have been mixed, and more research is needed.

Pain and Analgesia: PT-141 has been investigated for its potential analgesic (pain-relieving) effects, mediated through activation of melanocortin receptors in the spinal cord and brain. In preclinical studies, PT-141 has been shown to reduce pain sensitivity in various animal models of pain, including inflammatory pain, neuropathic pain, and visceral pain. The analgesic effects of PT-141 appear to be mediated through modulation of pain processing pathways in the spinal cord and brain, and through interactions with the endogenous opioid and cannabinoid systems. However, the clinical evidence for the analgesic effects of PT-141 in humans is limited, and more research is needed to determine the safety and efficacy of PT-141 for the treatment of pain.

Product Specifications

Product Name	PT-141 (Bremelanotide)
Full Name	Bremelanotide (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2)
Sequence	Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
Molecular Formula	C50H68N14O10
Molecular Weight	1025.2 g/mol
Purity	≥99%
Appearance	White lyophilized powder
Solubility	Soluble in water (10 mg/mL) and physiological buffers
Storage	Store at -20°C upon receipt. After reconstitution, store at 2-8°C for up to 30 days.
Available Sizes	5mg, 10mg, 20mg, 50mg
Quality Control	HPLC, Mass Spectrometry, COA provided

Reconstitution and Handling Guidelines

Proper reconstitution and handling are essential for maintaining the stability and efficacy of PT-141. Follow these guidelines carefully to ensure optimal results in your research.

Reconstitution Procedure:

1. Allow the vial to reach room temperature before opening (approximately 15-20 minutes).
2. Wipe the rubber stopper with an alcohol swab and allow it to dry.
3. Using a sterile syringe, inject the appropriate volume of bacteriostatic water or sterile saline into the vial. For a 10mg vial, add 2mL of solvent to achieve a concentration of 5mg/mL. For a 20mg vial, add 4mL of solvent for a 5mg/mL concentration.
4. Gently swirl the vial until the powder is completely dissolved. Do not shake vigorously, as this can denature the peptide. The solution should be clear and colorless.
5. Once fully dissolved, inspect the solution for any particles or discoloration. If you notice any particles or significant discoloration, do not use the solution.

Storage After Reconstitution:

• Store reconstituted PT-141 in a refrigerator at 2-8°C (36-46°F).
• When stored properly, reconstituted PT-141 remains stable for up to 30 days.
• For long-term storage (up to 6 months), aliquot the solution into individual doses and store at -20°C. Avoid repeated freeze-thaw cycles, as this can degrade the peptide.
• Do not store reconstituted peptide in direct sunlight or at room temperature for extended periods.

Handling Precautions:

• Always wear gloves and use sterile technique when handling PT-141.
• Use only sterile syringes and needles for reconstitution and administration.
• Do not mix PT-141 with other peptides or compounds in the same vial unless you have verified compatibility and stability.
• If you are using PT-141 for in vitro studies, dilute it to the desired concentration using appropriate buffer solutions.
• PT-141 can be administered via subcutaneous (SC) injection, intramuscular (IM) injection, or intranasal spray for in vivo studies. For SC or IM administration, rotate injection sites to minimize local reactions. For intranasal administration, use a suitable intranasal delivery device and follow the manufacturer’s instructions.

Frequently Asked Questions (FAQ)

Q1: What is PT-141 and how does it work?

A: PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide (7 amino acids) that is a modified analog of alpha-melanocyte-stimulating hormone (α-MSH). It works by binding to and activating the melanocortin receptors, a family of G-protein-coupled receptors that includes five subtypes (MC1-MC5). PT-141 has the highest affinity and potency for the MC4 receptor, which is highly expressed in the hypothalamus and other brain regions involved in sexual function, appetite regulation, and energy homeostasis. Activation of MC4 receptors in the hypothalamus increases the release of various neurotransmitters involved in sexual arousal, including dopamine, norepinephrine, oxytocin, and nitric oxide (NO), resulting in increased sexual desire, sexual arousal, and improved sexual function in both men and women. Unlike medications such as sildenafil (Viagra) and tadalafil (Cialis), which work by increasing blood flow to the genitals but do not directly affect sexual desire or libido, PT-141 works centrally in the brain to increase sexual desire and arousal, making it effective for both physical and psychological causes of sexual dysfunction. In addition to its effects on sexual function, PT-141 also has effects on appetite regulation (suppressing appetite and promoting weight loss), inflammation (reducing inflammation and immune activation), and pigmentation (increasing skin tanning through MC1 receptor activation). PT-141 was approved by the FDA in 2019 under the brand name Vyleesi® for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the first medication approved for this indication.

Q2: What is the difference between PT-141 and Melanotan II?

A: PT-141 (Bremelanotide) and Melanotan II are both synthetic cyclic heptapeptide analogs of alpha-melanocyte-stimulating hormone (α-MSH), and they have similar structures and mechanisms of action, but there are several important differences between them: (1) Structure: PT-141 has the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, while Melanotan II has the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 with an additional amide group at the C-terminus. Wait, actually, the structures are very similar, but PT-141 (Bremelanotide) is the active metabolite of Melanotan II. Melanotan II has an additional C-terminal amide group that is cleaved in the body to produce Bremelanotide (PT-141). So PT-141 is the active form of the peptide, while Melanotan II is a prodrug that is converted to PT-141 in the body. (2) Potency and selectivity: PT-141 (Bremelanotide) is generally considered to be more potent and more selective for the MC4 receptor than Melanotan II, which has higher affinity for the MC1 receptor (responsible for skin tanning) and may cause more skin pigmentation side effects. PT-141 has a more balanced receptor profile, with higher MC4/MC1 selectivity, resulting in more pronounced sexual effects and less skin tanning compared to Melanotan II. (3) Clinical development: PT-141 (Bremelanotide) has been extensively studied in clinical trials and is approved by the FDA for the treatment of HSDD in premenopausal women under the brand name Vyleesi®. Melanotan II, on the other hand, has not been approved for any clinical indication, and it is primarily sold as an unregulated “research chemical” or “tanning agent” online, with limited clinical data on its safety and efficacy. (4) Side effects: Both PT-141 and Melanotan II can cause similar side effects, including nausea, flushing, headache, and transient increases in blood pressure. However, Melanotan II may cause more skin pigmentation and tanning due to its higher MC1 receptor affinity, while PT-141 may cause more pronounced sexual effects due to its higher MC4 receptor selectivity. Additionally, Melanotan II has been associated with more frequent and more severe side effects in some reports, possibly due to its lower purity and lack of quality control in unregulated products. In summary, PT-141 (Bremelanotide) is the active, more potent, and more clinically developed form of the peptide, with a more favorable receptor profile and better safety data, while Melanotan II is a prodrug that is converted to PT-141 in the body, with more skin tanning effects and less clinical data. At Hanpro Peptides, we offer high-purity PT-141 (Bremelanotide) for research purposes, manufactured to the highest quality standards and tested for purity and identity by HPLC and mass spectrometry.

Q3: What is the recommended dosage for PT-141 in research studies?

A: The optimal dosage of PT-141 varies depending on the specific research application, animal model, route of administration, and desired outcome. In preclinical animal studies, dosages have ranged from 0.1 mg/kg to 10 mg/kg body weight per administration, depending on the species and study design. For rodent studies, typical dosages range from 0.5 mg/kg to 5 mg/kg per administration, administered via subcutaneous injection, intraperitoneal injection, or intranasal delivery. For larger animal models (such as non-human primates), dosages are typically lower, ranging from 0.1 mg/kg to 1 mg/kg per administration. For in vitro studies, concentrations typically range from 1 nM to 100 μM, with most studies using concentrations between 10 nM and 10 μM. It is important to note that these are research dosages and should not be interpreted as recommendations for human use. In clinical studies, PT-141 is typically administered via subcutaneous injection at dosages ranging from 0.5 mg to 20 mg per administration, or via intranasal spray at dosages ranging from 5 mg to 20 mg per administration. For the treatment of HSDD in premenopausal women, the FDA-approved dose of PT-141 (Vyleesi®) is 1.75 mg administered as an intranasal spray, as needed, approximately 45 minutes before anticipated sexual activity, with no more than one dose per 24-hour period and no more than 8 doses per month. For the treatment of erectile dysfunction and low libido in men, typical dosages in clinical trials have ranged from 5 mg to 20 mg per administration (subcutaneous injection) or 10 mg to 20 mg per administration (intranasal spray), administered as needed approximately 30-60 minutes before anticipated sexual activity. It is important to note that the effects of PT-141 are dose-dependent, with higher doses producing more pronounced sexual effects but also a higher incidence of side effects, particularly nausea, flushing, and transient increases in blood pressure. To minimize side effects, PT-141 is typically initiated at a low dose and gradually titrated up to the effective dose based on individual response and tolerability. Researchers should consult published literature and conduct dose-response studies to determine the optimal dosage for their specific research application. Always follow institutional guidelines and ethical protocols when conducting research with PT-141.

Q4: What are the most common side effects of PT-141?

A: PT-141 is generally well-tolerated in both preclinical and clinical studies, with a predictable and manageable side effect profile. The most common side effects of PT-141 are mild to moderate in severity, occur primarily within the first 1-2 hours after administration, and tend to diminish over time with repeated use. The most common side effects include: (1) Nausea: The most common side effect of PT-141, occurring in approximately 15-40% of patients, depending on the dose and route of administration. Nausea is generally mild to moderate in severity, occurs within the first 1-2 hours after administration, and typically resolves within 4-8 hours. The incidence of nausea is dose-dependent, with higher doses associated with a higher incidence of nausea. The incidence of nausea can be reduced by initiating treatment at a low dose and gradually titrating up, by taking the peptide with food, or by taking an anti-nausea medication (such as ondansetron) before administration. (2) Flushing and warmth of the skin: Occurring in approximately 10-30% of patients, flushing is caused by vasodilation (widening of blood vessels) and is similar to the “niacin flush” caused by high doses of nicotinic acid. Flushing is generally mild and transient, lasting 15-60 minutes, and it typically affects the face, neck, and chest. The incidence of flushing can be reduced by taking an aspirin or non-steroidal anti-inflammatory drug (NSAID) before administration, or by gradually increasing the dose over time. (3) Headache: Occurring in approximately 5-15% of patients, headaches are generally mild and transient, lasting 1-4 hours. The incidence of headaches can be reduced by staying hydrated and by taking an over-the-counter pain reliever (such as acetaminophen or ibuprofen) if needed. (4) Transient increases in blood pressure and heart rate: PT-141 can cause mild, transient increases in systolic blood pressure (typically 5-10 mmHg) and heart rate (typically 5-10 beats per minute), particularly at higher doses. These increases generally occur within the first 1-2 hours after administration and return to baseline within 4-8 hours. While these cardiovascular effects are generally mild and transient, PT-141 should be used with caution in patients with uncontrolled hypertension or cardiovascular disease, and blood pressure should be monitored during treatment. (5) Vomiting: Occurring in approximately 2-10% of patients, particularly at higher doses. Vomiting is generally mild and occurs within the first 1-2 hours after administration. The incidence of vomiting can be reduced by initiating treatment at a low dose and gradually titrating up, and by taking an anti-nausea medication before administration. (6) Injection site reactions: Including redness, swelling, itching, or pain at the injection site, occurring in approximately 2-10% of patients with subcutaneous or intramuscular administration. These reactions are generally mild and transient, and they can be reduced by rotating injection sites and using proper injection technique. (7) Increased skin pigmentation/tanning: Due to activation of the MC1 receptor in melanocytes, PT-141 can cause increased skin pigmentation and tanning, particularly with repeated use or at higher doses. This effect is generally mild and reversible upon discontinuation, but it may be undesirable for some patients. PT-141 should not be used as a “tanning agent” without medical supervision, as it may encourage excessive sun exposure and increase the risk of skin cancer. (8) Other less common side effects: Including dizziness, fatigue, nasal congestion (with intranasal administration), tingling or numbness, increased body temperature, and mood changes. These side effects are generally mild and transient. Serious side effects are rare, but they can include: (1) Severe allergic reactions, including rash, itching, hives, swelling of the face/lips/tongue, and difficulty breathing. If any of these symptoms occur, discontinue use immediately and seek medical attention. (2) Severe or persistent hypertension, particularly in patients with pre-existing cardiovascular disease. If blood pressure remains elevated for more than 4-6 hours after administration, seek medical attention. (3) Severe or persistent nausea and vomiting, which can lead to dehydration and electrolyte imbalances, particularly with repeated use. If nausea and vomiting are severe or persistent, seek medical attention. (4) Priapism (prolonged erection lasting more than 4 hours) in men, which is a medical emergency that requires immediate medical attention to prevent permanent damage to the penis. While priapism has not been commonly reported with PT-141, it is a potential risk with any medication that affects erectile function, and it should be treated as a medical emergency if it occurs. It is important to note that these side effects are based on clinical data from the FDA-approved formulation (Vyleesi®) and from clinical trials, and the side effect profile may vary depending on the dose, route of administration, purity of the product, and individual patient factors. Researchers should always follow proper safety protocols and consult institutional safety guidelines when working with PT-141.

Q5: Is PT-141 legal for research purposes?

A: Yes, PT-141 (Bremelanotide) is legal for research purposes in most countries, including the United States, when purchased from reputable suppliers and used strictly for laboratory research. PT-141 is an FDA-approved prescription medication (under the brand name Vyleesi®) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, but it is not a controlled substance, and it can be purchased for research purposes from reputable peptide suppliers. However, it is important to note that while PT-141 is approved for clinical use in premenopausal women with HSDD, the use of PT-141 for other indications (such as erectile dysfunction in men, low libido in men, or weight loss) is considered “off-label” use, and it should only be done under the supervision of a qualified healthcare provider. For research purposes, PT-141 can be purchased from reputable peptide suppliers and used in preclinical and clinical research studies in accordance with applicable regulations and institutional guidelines. It is important to purchase high-purity PT-141 from reputable suppliers that provide a Certificate of Analysis (COA) with each batch, verifying the purity, identity, and quality of the product. There are many unregulated online suppliers selling PT-141 and Melanotan II as “research chemicals” or “tanning agents,” and the quality and purity of these products can vary significantly, with many products containing impurities, contaminants, or incorrect dosages. For research purposes, it is important to purchase from reputable suppliers that manufacture their products in certified facilities and conduct rigorous quality control testing. Researchers must ensure that their use of PT-141 complies with all applicable local, state, and federal regulations, as well as institutional guidelines and ethical protocols. For in vivo research involving animals, researchers must follow institutional animal care and use committee (IACUC) guidelines, and for human subjects research, researchers must follow institutional review board (IRB) guidelines and obtain informed consent from participants. At Hanpro Peptides, we sell high-purity PT-141 (Bremelanotide) exclusively for research purposes, and all purchasers must agree to use the product only for legitimate scientific research. Our PT-141 is manufactured in state-of-the-art facilities and undergoes rigorous quality control testing, including HPLC analysis for purity (≥99%) and mass spectrometry for identity verification, and each batch comes with a detailed Certificate of Analysis (COA). It is important to note that while PT-141 is approved for clinical use in premenopausal women with HSDD, it has not been evaluated by the FDA for the treatment, cure, or prevention of other diseases or conditions, and it should not be used as a substitute for medical advice or treatment. Additionally, the use of PT-141 for bodybuilding, performance enhancement, or as a “tanning agent” without medical supervision is not recommended, as it may be associated with significant health risks, particularly with unregulated products of unknown purity and quality.

Q6: Can PT-141 be used in combination with other peptides or medications?

A: Yes, PT-141 can be used in combination with other peptides or medications for research purposes, and combination therapy is an active area of research. However, researchers should carefully consider the potential interactions, additive effects, and safety of combination therapy before using PT-141 in combination with other peptides or medications. Common combination therapies being investigated include: (1) PT-141 + PDE5 inhibitors (sildenafil, tadalafil, vardenafil): PT-141 is often used in combination with phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction (ED) in men, particularly in men who do not respond adequately to PDE5 inhibitors alone. PT-141 works centrally in the brain to increase sexual desire and arousal, while PDE5 inhibitors work peripherally to increase blood flow to the penis, and the two mechanisms may be synergistic. In clinical trials, the combination of PT-141 and sildenafil has been shown to improve erectile function more effectively than either medication alone in men with ED, including men with severe ED and men who do not respond to sildenafil alone. However, the combination may also increase the risk of side effects, particularly flushing, headache, and transient changes in blood pressure, and patients should be monitored carefully when using this combination. (2) PT-141 + Testosterone or other androgens: PT-141 may be used in combination with testosterone replacement therapy (TRT) or other androgens for the treatment of low libido and sexual dysfunction in men with low testosterone levels. Testosterone plays a key role in regulating sexual desire and function, and men with low testosterone often experience low libido, erectile dysfunction, and reduced sexual satisfaction. The combination of PT-141 (which increases sexual desire and arousal centrally) and testosterone (which supports overall sexual function and libido) may be more effective than either treatment alone in men with low testosterone and sexual dysfunction. However, the combination may also increase the risk of side effects, particularly polycythemia (increased red blood cell count), acne, and prostate enlargement, and patients should be monitored carefully when using this combination. (3) PT-141 + Growth hormone secretagogues (Ipamorelin, CJC-1295, Tesamorelin): PT-141 may be used in combination with growth hormone secretagogues for research purposes, particularly in studies investigating body composition, sexual function, and overall health and wellness. Growth hormone secretagogues increase growth hormone and IGF-1 levels, which can support muscle growth, fat loss, recovery, and overall health, while PT-141 increases sexual desire and function. The combination may provide synergistic benefits for overall health and quality of life, particularly in older adults or in individuals with age-related decline in growth hormone and sexual function. However, researchers should carefully monitor glucose levels, as growth hormone can increase blood glucose levels and may counteract some of the metabolic benefits of PT-141. (4) PT-141 + Melanocortin receptor agonists or other peptides: PT-141 may be used in combination with other melanocortin receptor agonists (such as Melanotan II or setmelanotide) or with other peptides (such as BPC-157, TB-500, GHK-Cu, etc.) for various research applications. However, researchers should carefully consider the potential interactions and safety of these combinations, as combining multiple melanocortin receptor agonists may increase the risk of side effects, particularly nausea, flushing, and cardiovascular effects, and there is limited research on the safety and efficacy of combining PT-141 with other peptides. (5) PT-141 + Antidepressants or other psychiatric medications: PT-141 may be used in combination with antidepressants (such as SSRIs or SNRIs) or other psychiatric medications for the treatment of sexual dysfunction caused by these medications (a common side effect of many antidepressants). PT-141 works centrally to increase sexual desire and arousal, which may counteract the sexual side effects of antidepressants. In clinical trials, PT-141 has been shown to improve sexual function in women with antidepressant-induced sexual dysfunction, and it may be effective for this indication in men as well. However, researchers should carefully consider the potential interactions between PT-141 and psychiatric medications, as there may be additive effects on neurotransmitter systems (particularly dopamine and serotonin) that could increase the risk of side effects or interactions. It is important to note that combination therapy may increase the risk of side effects, particularly nausea, flushing, headache, and cardiovascular effects, and researchers should always consult published literature and conduct appropriate safety studies before using PT-141 in combination with other peptides or medications. Always follow institutional guidelines and ethical protocols when conducting research with PT-141.

Q7: What is the shelf life of PT-141, and how should it be stored?

A: When stored properly, lyophilized (freeze-dried) PT-141 has a shelf life of up to 2 years from the date of manufacture when stored at -20°C in a freezer, protected from light and moisture. It is important to keep PT-141 in its original sealed vial, protected from light, moisture, and temperature fluctuations. PT-141 is a cyclic peptide with modified amino acids (Nle, D-Phe) and N-terminal acetylation/C-terminal amidation, which makes it highly stable and resistant to enzymatic degradation, but it can still degrade over time if exposed to light, moisture, or high temperatures. For short-term storage (up to 3 months), PT-141 can be stored at 2-8°C (refrigerator), protected from light and moisture. For long-term storage (up to 2 years), PT-141 should be stored at -20°C (freezer), protected from light and moisture. It is important to avoid repeated freeze-thaw cycles, as this can cause degradation. After reconstitution, PT-141 should be stored in a refrigerator at 2-8°C, protected from light, and used within 30 days. For longer storage of reconstituted PT-141 (up to 6 months), it is recommended to aliquot the solution into individual doses and store at -20°C, protected from light. However, repeated freeze-thaw cycles should be avoided, as they can degrade the peptide. Always check the product’s expiration date and Certificate of Analysis (COA) for specific storage recommendations. At Hanpro Peptides, all our products are shipped with cold packs to maintain stability during transit, and each vial comes with a detailed COA specifying the manufacture date, expiration date, and purity level. It is important to note that PT-141 should not be stored at room temperature for extended periods, as exposure to heat, light, and moisture can lead to degradation of the peptide and reduced efficacy. The reconstituted solution should be inspected regularly for any signs of degradation, including discoloration, cloudiness, or particle formation. If any of these signs are observed, the solution should be discarded and not used for research purposes. Additionally, PT-141 is stable under a wide range of pH conditions (pH 3-9), but it is most stable at slightly acidic pH (pH 4-6), and it can degrade at extreme pH values or at high temperatures, so it is important to use appropriate buffers when working with reconstituted PT-141.

Related Products for Research

For researchers investigating sexual function, hormonal health, and related conditions, we recommend exploring these related peptides:

• Ipamorelin – A growth hormone secretagogue that stimulates the release of growth hormone, supporting muscle growth, fat loss, recovery, and overall health. Often studied in combination with PT-141 for comprehensive health and wellness research.
• CJC-1295 Without DAC – A growth hormone-releasing hormone (GHRH) analog that increases growth hormone and IGF-1 levels, supporting muscle growth, fat loss, and recovery. Frequently studied in combination with Ipamorelin and PT-141.
• Tesamorelin – A growth hormone-releasing hormone (GHRH) analog that increases growth hormone and IGF-1 levels, specifically studied for the reduction of visceral adipose tissue (belly fat) in HIV-associated lipodystrophy. Often studied in combination with PT-141 for body composition research.
• BPC 157 – A 15-amino-acid peptide derived from gastric juice, known for its remarkable healing properties, including tissue repair, gut health, and recovery. Often studied in combination with PT-141 for overall health and recovery research.
• TB-500 (Thymosin Beta-4) – A 43-amino-acid peptide known for its connective tissue healing and flexibility-promoting properties. Often studied in combination with PT-141 for recovery and physical performance research.
• GHK-Cu (Copper Peptide) – A naturally occurring tripeptide with copper, known for its anti-aging, wound healing, and tissue regeneration properties. Often studied in combination with PT-141 for skin health and anti-aging research.
• Epithalon – A synthetic peptide derived from the pineal gland, known for its anti-aging and telomere-lengthening properties. Often studied in combination with PT-141 for comprehensive anti-aging and longevity research.
• NAD+ (Nicotinamide Adenine Dinucleotide) – A vital coenzyme involved in cellular energy metabolism, DNA repair, and longevity. Often studied in combination with PT-141 for overall health, energy, and anti-aging research.

Quality Assurance at Hanpro Peptides

At Hanpro Peptides, we are committed to providing researchers with the highest quality peptides available. Our PT-141 is manufactured in state-of-the-art facilities using advanced solid-phase peptide synthesis (SPPS) technology, ensuring consistent quality and purity batch after batch. The cyclic structure and modified amino acids (Nle, D-Phe) are carefully incorporated during the synthesis process to ensure proper folding, receptor binding, and biological activity.

Our Quality Control Process Includes:

• High-Performance Liquid Chromatography (HPLC): Every batch is analyzed by HPLC to verify purity ≥99%. This ensures that our products are free from impurities and contaminants that could affect research results.
• Mass Spectrometry (MS): Mass spectrometry is used to confirm the molecular weight and identity of each peptide, ensuring that the product matches the expected amino acid sequence and modifications.
• Cyclic Structure Verification: For cyclic peptides like PT-141, we conduct additional testing to verify proper cyclization and folding, ensuring that the peptide has the correct three-dimensional structure for optimal receptor binding and biological activity.
• Certificate of Analysis (COA): Every product comes with a detailed COA that includes the batch number, manufacture date, expiration date, purity level, and test results. Researchers can use this information to verify product quality and document their research materials.
• Microbiological Testing: Our products undergo rigorous microbiological testing to ensure they are free from bacteria, fungi, and other microorganisms.
• Endotoxin Testing: For peptides intended for in vivo studies, we conduct endotoxin testing to ensure that levels are within acceptable limits for research use.

We also offer custom peptide synthesis services for researchers who require specific sequences, modifications, or formulations. Our team of experienced chemists can synthesize a wide range of peptides, including cyclic peptides, modified peptides, and peptide conjugates, tailored to your specific research needs. We can also provide custom formulations, including liposomal formulations, nanoparticle formulations, and controlled-release formulations, to improve the bioavailability and efficacy of your research peptides.

Disclaimer

Important Notice: All products sold by Hanpro Peptides are intended for laboratory research purposes only. They are not intended for human consumption, diagnostic use, or therapeutic application. While PT-141 (Bremelanotide) is approved by the FDA for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women under the brand name Vyleesi®, our research-grade PT-141 is not intended for clinical use or human consumption, and it should only be used in preclinical research or approved clinical trials in accordance with applicable regulations and institutional guidelines.

Researchers are responsible for ensuring that their use of our products complies with all applicable local, state, and federal regulations, as well as institutional guidelines and ethical protocols. Our products should only be used by qualified researchers in properly equipped laboratory settings. Animal research should be conducted in accordance with institutional animal care and use committee (IACUC) guidelines, and human subjects research should be conducted in accordance with institutional review board (IRB) guidelines and under an active investigational new drug (IND) application where required.

The information provided in this product description is for educational and informational purposes only and is based on published scientific literature and clinical trial results. It does not constitute medical advice, and we make no claims regarding the therapeutic effects or safety of our products for human use. Any references to potential therapeutic applications are based on preclinical and clinical research and are not intended to suggest that these products are safe or effective for human consumption.

By purchasing and using our products, you acknowledge and agree that you are a qualified researcher, that you will use our products only for legitimate scientific research, and that you assume all responsibility for ensuring compliance with applicable regulations and ethical guidelines.

If you have any questions about our products, quality control processes, or custom synthesis services, please contact our customer support team. We are committed to providing researchers with the highest quality products and exceptional customer service to support your important research endeavors.